Frazier adds $780M fund for its ‘growth buyout’ team; FDA pushes back its deadline on AbbVie's elagolix; Promethera buys NASH drug
→ Frazier Healthcare Partners has put together a $780 million fund for its “growth buyout” group to invest. A busy life sciences investor, this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
